Morgan Stanley
GLUE icon

Morgan Stanley’s Monte Rosa Therapeutics GLUE Stock Holding History

Morgan Stanley’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.1M Buy
789,545
+105,482
+15% +$1.99M ﹤0.01% 3137
2026
Q1 		$11.3M Sell
684,063
-121,467
-15% -$2.32M ﹤0.01% 3474
2025
Q4 		$12.6M Buy
805,530
+160,334
+25% +$2.16M ﹤0.01% 3388
2025
Q3 		$4.78M Buy
645,196
+74,746
+13% +$396K ﹤0.01% 4193
2025
Q2 		$2.57M Buy
570,450
+148,360
+35% +$662K ﹤0.01% 4548
2025
Q1 		$1.96M Sell
422,090
-1,833,263
-81% -$11.2M ﹤0.01% 4613
2024
Q4 		$15.7M Buy
2,255,353
+2,130,021
+1,700% +$16M ﹤0.01% 2996
2024
Q3 		$664K Buy
125,332
+56,990
+83% +$288K ﹤0.01% 5263
2024
Q2 		$256K Buy
68,342
+12,612
+23% +$64.3K ﹤0.01% 5570
2024
Q1 		$393K Sell
55,730
-25,746
-32% -$153K ﹤0.01% 5418
2023
Q4 		$460K Buy
81,476
+45,410
+126% +$178K ﹤0.01% 5329
2023
Q3 		$173K Sell
36,066
-15,014
-29% -$96.7K ﹤0.01% 5648
2023
Q2 		$350K Buy
51,080
+12,850
+34% +$83.1K ﹤0.01% 5395
2023
Q1 		$298K Sell
38,230
-69,467
-65% -$483K ﹤0.01% 5518
2022
Q4 		$820K Sell
107,697
-14,426
-12% -$120K ﹤0.01% 4972
2022
Q3 		$996K Sell
122,123
-17,526
-13% -$161K ﹤0.01% 4882
2022
Q2 		$1.35M Buy
139,649
+4,970
+4% +$49.9K ﹤0.01% 4817
2022
Q1 		$1.89M Sell
134,679
-1,260
-0.9% -$17.5K ﹤0.01% 4555
2021
Q4 		$2.77M Buy
135,939
+42,038
+45% +$880K ﹤0.01% 4302
2021
Q3 		$2.09M Buy
+93,901
New +$2.69M ﹤0.01% 4531

Other funds holding GLUE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley's GLUE Position: Q2 2026 in Review

Morgan Stanley increased its Monte Rosa Therapeutics (GLUE) stake by 15% in Q2 2026, buying an estimated $1.99M and bringing the position to 789,545 shares worth $19.1M. The position accounts for ﹤0.01% of the portfolio, ranked #3137.

Morgan Stanley first reported a position in GLUE in Q3 2021 and has held it in 20 quarters since. 193 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

  • Morgan Stanley held 789,545 shares of Monte Rosa Therapeutics worth $19.1M as of Q2 2026.
  • Morgan Stanley bought 105,482 Monte Rosa Therapeutics shares in Q2 2026, an estimated $1.99M.
  • Monte Rosa Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #3137 holding.
  • Morgan Stanley first reported a position in Monte Rosa Therapeutics in Q3 2021 and has held it in 20 quarters since.
  • 193 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.